.png){kind=icon}
.png){kind=icon}
Return
Ustekinumab: moving the target from psoriasis to Crohn's disease
.png){kind=icon}
PRE
AI
A
M
F
V
DOI：10.1586/17474124.2014.850414.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Crohn's disease (CD) is an inflammatory bowel disease whose precise etiology is still unknown, and therefore a causal therapy is not yet available. Studies showing the overexpression of IL-12 and IL-23, polymorphisms in genes encoding those cytokines and their receptors and genome-wide association studies have linked Crohn's pathogenesis with IL-12/23 pathway. Ustekinumab is a novel therapeutic IgG(1) kappa monoclonal antibody that modulates Th1 and Th17 function, by blocking the p40 subunit of both IL-12 and IL-23 and preventing the interaction with their receptors on T cells, natural killer cells and antigen-presenting cells with established efficacy in psoriasis. This review will mainly focus on the available evidence on the role of ustekinumab in moderate-to-severe CD. The potential role of this biologic in the armamentarium of CD therapy is discussed.
Keywords:
Crohn's disease
IL-23
IL-12
inflammatory bowel disease
psoriasis
ustekinumab
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
2.5
Papers:
1.7K
Citations:
3.7K
Organization
Cited Papers